MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00432-019-02910-6

Медицинская библиотека · Journal of cancer research and clinical oncology · 2019

Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).

Möbius Susanne, Schenk Thomas, Himsel Danny, Maier Jacqueline, Franke Georg-Nikolaus, Saussele Susanne, Pott Christiane, Andrikovics Hajnalka, Meggyesi Nora, Machova-Polakova Katerina, Zizkova Hana, Jurcek Tomáš, Mesanovic Semir, Zadro Renata, Gottardi Enrico, Haenig Jens, Schuld Peter, Cross Nicholas C P, Hochhaus Andreas, Ernst Thomas

СтатьяПеревод в очереди

Аннотация

PURPOSE: The advent of tyrosine kinase inhibitor (TKI) therapies has revolutionized the treatment of chronic myeloid leukemia (CML). The European LeukemiaNet (ELN) recommends quantification of BCR-ABL1 transcripts by real-time quantitative PCR every 3 months during TKI treatment. Since a proportion of patients in deep molecular response (DMR: MR4, MR4.5, MR5) maintain remission after treatment stop, assessment of DMR is crucial. However, systematically collected molecular data, monitored with sensitive standardized assays, are not available outside clinical trials.

METHODS

Data were collected on the standardized assessment of molecular response in the context of real-life practice. BCR-ABL1 transcript levels after > 2 years of TKI therapy were evaluated for DMR by local laboratories as well as standardized EUTOS laboratories. Since standardized molecular monitoring is a prerequisite for treatment discontinuation, central surveillance of the performance of the participating laboratories was carried out.

RESULTS

Between 2014 and 2017, 3377 peripheral blood samples from 1117 CML patients were shipped to 11 standardized reference laboratories in six European countries. BCR-ABL1 transcript types were b3a2 (41.63%), b2a2 (29.99%), b2a2/b3a2 (3.58%) and atypical (0.54%). For 23.72% of the patients, the initial transcript type had not been reported. Response levels (EUTOS laboratory) were: no MMR, n = 197 (6.51%); MMR, n = 496 (16.40%); MR4, n = 685 (22.64%); MR4.5, n = 937 (30.98%); MR5, n = 710 (23.47%). With a Cohen's kappa coefficient of 0.708, a substantial agreement between EUTOS-certified and local laboratories was shown.

CONCLUSIONS

Multicenter DMR assessment is feasible in the context of real-life clinical practice in Europe. Information on the BCR-ABL1 transcript type at diagnosis is crucial to accurately monitor patients' molecular response during or after TKI therapy.

Для цитирования: Möbius Susanne, Schenk Thomas, Himsel Danny, Maier Jacqueline, Franke Georg-Nikolaus, Saussele Susanne, Pott Christiane, Andrikovics Hajnalka, Meggyesi Nora, Machova-Polakova Katerina, Zizkova Hana, Jurcek Tomáš, Mesanovic Semir, Zadro Renata, Gottardi Enrico, Haenig Jens, Schuld Peter, Cross Nicholas C P, Hochhaus Andreas, Ernst Thomas. Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).. Journal of cancer research and clinical oncology. 2019. DOI: 10.1007/s00432-019-02910-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.